Announcement on Progress in Repurchasing Shares

Securities code: 688075 Securities abbreviation: Anxu Biotechnology Announcement number: 2026-031

Hangzhou Anxu Biotechnology Co., Ltd.

Announcement on progress of share repurchase

The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.

Important content reminder:

The first disclosure date of the repurchase plan is 2026/4/1, proposed by the company’s board of directors

The implementation period of the buyback plan is from April 1, 2026 to March 29, 2027

The estimated repurchase amount is 25 million yuan to 49 million yuan

□Reduce registered capital

√Used for employee stock ownership plans or equity incentives

Repurchase purpose

□Used to convert company convertible bonds

□To protect the company’s value and shareholders’ rights and interests

The cumulative number of shares repurchased is 707,939 shares

The cumulative number of repurchased shares accounts for 0.5571% of the total share capital.

The cumulative repurchased amount is 25.3445 million yuan

The actual repurchase price range is 27.95 yuan/share~38.87 yuan/share

1. Basic information on share repurchase

Hangzhou Anxu Biotechnology Co., Ltd. (hereinafter referred to as the "Company") held the fourth meeting of the third board of directors on March 30, 2026, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions", agreeing that the company will use its own funds to repurchase some of the company's issued RMB ordinary shares (A shares) through centralized bidding transactions, and all the repurchased shares will be used for employee stock ownership plans or equity incentives at an appropriate time in the future. The total amount of funds for this repurchase shall not be less than RMB 25 million (inclusive) and shall not exceed RMB 49 million (inclusive), and the repurchase price shall not exceed RMB 41 per share (inclusive). The repurchase period is 12 months from the date the company's board of directors considers and approves the share repurchase plan. For details, please refer to the "Anxu Biotech's Announcement on the Share Repurchase Plan through Centralized Bidding Transactions" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on April 1, 2026 (Announcement No.: 2026-007).

Due to the company's implementation of the annual equity distribution in 2025, the company's price limit for repurchasing shares this time has been adjusted from no more than RMB 41.00 per share (inclusive) to no more than RMB 40.2 per share (inclusive). For details, please refer to the "Announcement on Adjusting the Price Cap for Repurchased Shares after the Implementation of the Annual Equity Distribution in 2025" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on July 3, 2026 (Announcement No.: 2026-027).

2. Progress of share repurchase

According to the "Share Repurchase Rules of Listed Companies", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, during the period of repurchase, the company shall announce the progress of the repurchase as of the end of the previous month within the first three trading days of each month. The progress of the company's share repurchase is now announced as follows: As of August 31, 2026, the company has repurchased a total of 707,939 shares through a special securities account for share repurchase through centralized bidding transactions, accounting for 0.5571% of the company's total share capital of 127,082,805 shares. The highest price of the repurchase transaction was 38.87 yuan/share, and the lowest price was 27.95 Yuan/share, the total amount of funds paid is RMB 25,344,450.67 (excluding stamp duty, transaction commission and other transaction fees).

The progress of this share repurchase is in compliance with laws and regulations and the company's share repurchase plan.

3. Other matters

The company will strictly abide by the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, make repurchase decisions based on market conditions within the repurchase period and implement them. At the same time, it will perform information disclosure obligations in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.

Announcement is hereby made.

Board of Directors of Hangzhou Anxu Biotechnology Co., Ltd.

September 2, 2026